Ann Dermatol.  2015 Apr;27(2):184-189. 10.5021/ad.2015.27.2.184.

Comparison of Treatment Goals for Moderate-to-Severe Psoriasis between Korean Dermatologists and the European Consensus Report

• Youn SW
• Kim BR
• Lee JH
• Song HJ
• Choe YB
• Choi JH
• Kim NI
• Kim KJ
• Youn JI

• KMID: 2264808
• DOI: http://doi.org/10.5021/ad.2015.27.2.184

Abstract

BACKGROUND
The development of therapies for psoriasis has led to the need for a new strategy to the treatment of patients with moderate-to-severe psoriasis. New consensus guidelines for psoriasis treatment have been developed in some countries, some of which have introduced treatment goals to determine the timing of therapeutic regimens for psoriasis.
OBJECTIVE
To investigate the opinions held by Korean dermatologists who specialize in psoriasis about treatment goals, and to compare these with the European consensus.
METHODS
Korean dermatologists who specialize in psoriasis were asked 11 questions about defining the treatment goals for psoriasis. The questionnaire included questions about the factors used to classify the severity of psoriasis, defining the induction and maintenance phases of psoriasis treatment, defining treatment responses during the induction phase, and defining treatment responses during the maintenance phase.
RESULTS
The Korean consensus showed responses that were almost similar to the European consensus, even without using the Delphi technique, which uses repeated rounds of questions to reach a consensus. Only one response that related to psoriasis severity in the context of the quality of patients' lives differed from the European consensus.
CONCLUSION
The concept of using treatment goals in the treatment of moderate-to-severe psoriasis can be applied to Korean psoriasis patients. Since a tool for assessing the quality of patients' lives is not commonly used in Korea, the development of a simple, rapidly completed, and region-specific health-related quality of life assessment tool would enable treatment goals to be used in routine clinical practice.

Keyword

Consensus; Psoriasis; Severity of illness index; Treatment goal

MeSH Terms

Consensus*
Delphi Technique
Humans
Korea
Psoriasis*
Quality of Life
Severity of Illness Index
Surveys and Questionnaires

Figure

• 

  Fig. 1 Korean treatment goals for moderate-to-severe plaque psoriasis, which were revised from the European consensus. An assessment tool for measuring health-related quality of life issues in Korean patients should be developed further. An objective cut-off value should be validated. PASI: psoriasis area and severity index, HRQoL: health-related quality of life.

Reference

1. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009; 361:496–509.

2. Galadari I, Sharif MO, Galadari H. Psoriasis: a fresh look. Clin Dermatol. 2005; 23:491–502.

3. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM;; Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013; 133:377–385.

4. Hsu S, Papp KA, Lebwohl MG, Bagel J, Blauvelt A, Duffin KC, National Psoriasis Foundation Medical Board, et al. Consensus guidelines for the management of plaque psoriasis. Arch Dermatol. 2012; 148:95–102.

5. Pathirana D, Nast A, Ormerod AD, Reytan N, Saiag P, Smith CH, et al. On the development of the European S3 guidelines on the systemic treatment of psoriasis vulgaris: structure and challenges. J Eur Acad Dermatol Venereol. 2010; 24:1458–1467.

6. Ohtsuki M, Terui T, Ozawa A, Morita A, Sano S, Takahashi H, et al. Japanese guidance for use of biologics for psoriasis (the 2013 version). J Dermatol. 2013; 40:683–695.

7. Smith CH, Anstey AV, Barker JN, Burden AD, Chalmers RJ, Chandler DA, Chair of Guideline Group, et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol. 2009; 161:987–1019.

8. Kragballe K, Gniadecki R, Mørk NJ, Rantanen T, Ståhle M. Implementing best practice in psoriasis: a Nordic expert group consensus. Acta Derm Venereol. 2014; 94:547–552.

9. Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths CE, Nast A, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011; 303:1–10.

10. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994; 19:210–216.

11. Finlay AY, Basra MK, Piguet V, Salek MS. Dermatology life quality index (DLQI): a paradigm shift to patient-centered outcomes. J Invest Dermatol. 2012; 132:2464–2465.

12. Gupta AK, Pandey SS, Pandey BL. Effectiveness of conventional drug therapy of plaque psoriasis in the context of consensus guidelines: a prospective observational study in 150 patients. Ann Dermatol. 2013; 25:156–162.

13. Lee YW, Park EJ, Kwon IH, Kim KH, Kim KJ. Impact of psoriasis on quality of life: relationship between clinical response to therapy and change in health-related quality of life. Ann Dermatol. 2010; 22:389–396.

14. Zweegers J, van den Reek JM, van de Kerkhof PC, Otero ME, Ossenkoppele PM, Njoo MD, et al. Comparing treatment goals for psoriasis with treatment decisions in daily practice: results from a prospective cohort of patients with psoriasis treated with biologics: BioCAPTURE. Br J Dermatol. 2014; 171:1091–1098.